Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study
Authors' conclusion
People were given colchicine prophylaxis despite commonly having preexisting prescriptions for medications with potential to interact with colchicine. Adverse events were more common in people who had more comorbidities and certain potentially interacting medications.
Study context
- Population
- Adults initiating allopurinol for gout with colchicine prophylaxis, UK, 1 April 1997 to 30 November 2016 (mean age 63.9 [SD 14.7] years, 78.2% male)
- Participants
- 13,945 adults
- Outcome
- Likelihood of adverse events (diarrhoea, nausea or vomiting, MI, neuropathy, myalgia, myopathy, rhabdomyolysis, bone marrow suppression) by potential prognostic factors
Methodological detailslinked UK Clinical Practice Research Datalink and Hospital Episode Statistics datasets
- Linked UK Clinical Practice Research Datalink and Hospital Episode Statistics datasets
Main finding
As reported in the abstract
Prognostic factors for colchicine prophylaxis-related adverse events
Prescribed ≥1 potentially interacting medicine
26%, 95% CI 25%, 27%
Prescribed statins (most common interacting medicine)
21%, 95% CI 20%, 22%
Observational data: associations, not effects.
Original publication
Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study. Rheumatology (Oxford). Published 18 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →